- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00253968
Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia (GEMS)
February 2, 2016 updated by: Sanofi
Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia: a 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study
The purpose of the study is to assess efficacy and safety of eplivanserin in the population of patients complaining of sleep maintenance insomnia.
The patients suffering from that condition frequently wake up during the night, their sleep is nonrestorative and they suffer from a significant distress or impairment in their daily activities consecutive to insomnia.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
12 weeks for each patient (double-blind period) + 1 week of run-in (placebo), and 2 weeks of run-out (placebo)
Total Duration of observation: 15 weeks for each patient
Study Type
Interventional
Enrollment (Actual)
967
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Buenos Aires, Argentina
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Macquarie Park, Australia
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Laval, Canada
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Santiago, Chile
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Praha, Czech Republic
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Paris, France
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Berlin, Germany
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Mexico, Mexico
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Gouda, Netherlands
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Barcelona, Spain
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Guildford, United Kingdom
- Sanofi-Aventis Administrative Office
-
-
-
-
New Jersey
-
Bridgewater, New Jersey, United States, 08807
- Sanofi-Aventis Administrative Office
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Out patients
- Each patient must have primary insomnia in accordance with DSM-IV-TR-Axis I (Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition-Text Revision) criteria
- Based on patient's information, the patient must complain of at least one hour of wakefulness after sleep onset for at least 3 nights per week over the preceding month
- Patient must report impact daytime functioning associated with sleep maintenance insomnia as measured by question 3 of Insomnia Severity Index at screening visit and randomization visit.
Exclusion Criteria:
- Females who are lactating or pregnant
- Woman of childbearing potential with a positive serum beta human chorionic gonadotropin pregnancy test at screening and not using an acceptable form of contraception
- Patients presenting with acute or chronic pain resulting in insomnia
- Patients with history of epilepsy or seizures
- Consumption of xanthine containing beverage (i.e. tea, coffee, or cola) comprising more than 5 glasses/day
- Evidence of any clinically significant, severe, or unstable acute or chronically progressive medical or surgical disorder which may affect patient safety
- BMI >32
- Acute or chronic pain resulting in insomnia
- Patients with current psychiatric disorders according to DSM-IV-TR criteria, mental retardation, or dementia
- Clinically significant and abnormal EKG (QTc interval >=500 msec)
- Positive for hepatitis B or C
- Serious head injury or stroke within 1 year
- Use of OTC (over-the-counter) medications such as valerian root, kava, melatonin, St. John's Wort, or alluna; prescription sleep medications or anxiolytics within 1 week or 5 half-lives
- Participation in another trial within two month before the screening visit
- Use of any substance with psychotropic effects or properties known to affect sleep/wake
- Unable to complete the study questionnaires
- Night shift workers, and individuals who nap 3 or more times per week over the preceding month
History of:
- Primary hypersomnia
- Narcolepsy
- Breathing-related sleep disorder (such as sleep apnea)
- Circadian rhythm sleep disorder
- Parasomnia (somnambulism)
- Dyssomnia (such as periodic leg movements)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Eplivanserin
Eplivanserin 5 mg/day
|
oral administration
Other Names:
|
Placebo Comparator: Placebo
Placebo of Eplivanserin 5 mg /day
|
oral administration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline of the mean pr-WASO (wake time after sleep onset using patient's sleep questionnaire)
Time Frame: at week 12
|
at week 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline of the mean of the FOSQ (Functional Outcome of Sleep Questionnaire) items 1 and 2 (concentration/memory)
Time Frame: at week 12
|
at week 12
|
Change from baseline of the mean of the FOSQ items 4 and 10 (hobby/work)
Time Frame: at week 12
|
at week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2005
Primary Completion (Actual)
January 1, 2008
Study Completion (Actual)
January 1, 2008
Study Registration Dates
First Submitted
November 14, 2005
First Submitted That Met QC Criteria
November 14, 2005
First Posted (Estimate)
November 15, 2005
Study Record Updates
Last Update Posted (Estimate)
March 1, 2016
Last Update Submitted That Met QC Criteria
February 2, 2016
Last Verified
February 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Sleep Initiation and Maintenance Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Serotonin Agents
- Serotonin Antagonists
- SR 46349B
Other Study ID Numbers
- LTE6217
- 2005-003080-23 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insomnia
-
Leiden UniversityBioClock Consortium; Caring UniveristiesCompleted
-
National Science Council, TaiwanCompleted
-
Sunshine Lake Pharma Co., Ltd.Unknown
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Massachusetts General HospitalNational Institutes of Health (NIH)Completed
-
IpsenCompletedThe Effectiveness of Circadin in Improving Quality of Sleep in Patients Aged 55 or Over (QUALISLEEP)InsomniaRussian Federation
-
Charite University, Berlin, GermanyCompleted
-
Roxane LaboratoriesCompleted
-
Butler HospitalSunovionCompleted
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States